These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 10478177)

  • 21. [Low-dose rate intracavitary afterloading radiotherapy for cancer of uterine cervix].
    Zhang X; Wang Y; Wang H
    Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):294-6. PubMed ID: 12515631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gynecologic brachytherapy--from low-dose-rate to high-tech].
    Herrmann T; Christen N; Alheit HD
    Strahlenther Onkol; 1993 Mar; 169(3):141-51. PubMed ID: 8465248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Advances in brachytherapy--focusing on the permanent implant for early prostate carcinoma].
    Hirokawa Y
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2056-61. PubMed ID: 14712765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
    Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of high-dose rate brachytherapy in locally advanced prostate cancer.
    Vicini FA; Vargas C; Edmundson G; Kestin L; Martinez A
    Semin Radiat Oncol; 2003 Apr; 13(2):98-108. PubMed ID: 12728439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Present status of brachytherapy].
    Hahimoto S; Dokiya T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):885-93. PubMed ID: 3963855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current status and future of brachytherapy].
    Shigematsu Y; Masaki N; Ikeda H; Nishiyama K; Morimoto K; Ozeki S
    Gan No Rinsho; 1983 May; 29(6):695-701. PubMed ID: 6876438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma.
    Fayed A; Mutch DG; Rader JS; Gibb RK; Powell MA; Wright JD; Elnaqa I; Zoberi I; Grigsby PW
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):480-4. PubMed ID: 17141980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer.
    Wang CJ; Huang EY; Sun LM; Chen HC; Fang FM; Hsu HC; Changchien CC; Leung SW
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):179-89. PubMed ID: 15093915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality assurance of HDR prostate plans: program implementation at a community hospital.
    Rush JB; Thomas MD
    Med Dosim; 2005; 30(4):243-8. PubMed ID: 16275567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of the appropriate fraction number and size of the HDR brachytherapy for cervical cancer.
    Liu WS; Yen SH; Chang CH; Yang KM; Wu YP; Chen KY
    Gynecol Oncol; 1996 Feb; 60(2):295-300. PubMed ID: 8631555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
    Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B
    Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer.
    Shah C; Lanni TB; Ghilezan MI; Gustafson GS; Marvin KS; Ye H; Vicini FA; Martinez AA
    Brachytherapy; 2012; 11(6):441-5. PubMed ID: 22728157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Acute adverse effects of high dose brachytherapy in combination with external radiotherapy in localized prostate cancer].
    Soumarová R; Homola L; Stursa M; Perková H
    Cas Lek Cesk; 2006; 145(1):43-9. PubMed ID: 16468241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
    Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interstitial high-dose-rate brachytherapy in the treatment of base of tongue carcinoma.
    Takácsi-Nagy Z; Polgár C; Oberna F; Somogyi A; Major T; Remenár E; Fodor J; Kásler M; Németh G
    Strahlenther Onkol; 2004 Dec; 180(12):768-75. PubMed ID: 15592696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant high-dose-rate and low-dose-rate brachytherapy with external beam radiation in soft tissue sarcoma: a comparison of outcomes.
    Pohar S; Haq R; Liu L; Koniarczyk M; Hahn S; Damron T; Aronowitz JN
    Brachytherapy; 2007; 6(1):53-7. PubMed ID: 17284387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.